Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2005

View Archived Issues

Levetiracetam improves chorea symptoms in patients with Huntington's disease

Ralfinamide induces analgesic effects in patients with neuropathic pain

VasoGenix and QLT to develop new treatment for congestive heart failure

CT-011 completes phase I study in advanced hematological malignancies

Intercell and Biological E sign Asia agreement for Japanese encephalitis vaccine

FDA clears phase I study of systemic administered Reolysin

AustCancer submits DMF for GPI-0100

Innovate Oncology acquires rights to Capridine-Beta for prostate cancer

BAL-5788 enters hospital-acquired pneumonia phase III trials

Fosamax Plus D receives FDA approval

Celgene completes Revlimid NDA submission for MDS

Eisai and Abbott to develop adalimumab for psoriasis in Japan

Bausch & Lomb discloses new therapeutic agents for ophthalmic diseases

Retisert receives FDA approval

New patents cover treatments for pain and inflammation

New data on the antiviral efficacy and the PK of celgosivir

Long-term effects of transdermal rotigotine in patients with early PD

A new study confirms the benefits of eszopiclone in chronic insomnia

Lasofoxifene induces no adverse effects on mood and cognition in postmenopausal women

Japanese manufacturing approval for tocilizumab for Castleman's disease

Japanese manufacturing approval for Lulicon

Promising results from in vitro and in vivo testing of human rhinovirus inhibitor

Prana will not advance PBT-1 into PLACQUE study

Long-acting naltrexone reduces heavy drinking in alcohol-dependent subjects

Phase III results on lucinactant in premature infants at risk for RDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...